Quick Facts
Plain-English Summary
Vesugen is a synthetic tripeptide consisting of three amino acids — lysine, glutamic acid, and aspartic acid (Lys-Glu-Asp) — belonging to the Khavinson series of short peptide bioregulators. This class of compounds was developed from the 1970s onward at the St. Petersburg Institute of Bioregulation and Gerontology under Vladimir Khavinson, working within a Soviet and later Russian research tradition distinct from Western peptide pharmacology. The series is founded on the hypothesis that short peptides extracted from specific tissue types can act as organ-specific biological regulators, promoting cellular differentiation and counteracting age-related decline in the corresponding tissue.
Vesugen is designated as the vascular bioregulator within this series, purportedly developed from bovine vascular endothelium. Its proposed function is to promote endothelial cell health and function — particularly in aging vascular tissue — through gene-regulatory interactions at the cellular level. The Khavinson model proposes that these peptides interact with chromatin and gene-regulatory proteins to modulate gene expression patterns that govern cell differentiation and longevity.
The available research on Vesugen specifically is narrow. Studies come primarily from Khavinson's own institute, appear largely in Russian-language or Eastern European journals, and examine in vitro endothelial cell models and limited animal data rather than controlled human trials. A small number of publications by Trofimova SV and collaborators have examined vascular biomarkers in elderly subjects, but these do not constitute registered clinical trials and have not been published in major peer-reviewed Western journals.
The Khavinson peptide series as a whole suffers from a significant structural limitation: the overwhelming majority of research originates from a single institute and has not been independently replicated by external research groups. This is a critical constraint on interpreting the evidence, regardless of the mechanistic plausibility of the framework.
Vesugen is among the least-discussed compounds in the English-language biohacker community compared to better-known Khavinson peptides such as Epithalon. It has attracted modest interest in longevity research circles interested in vascular aging, but receives little systematic attention. Claims circulating in commercial vendor and supplement marketing channels — including assertions about reversing arterial aging or preventing cardiovascular disease — substantially exceed what the available evidence supports.
Mechanism of Action
Proposed mechanisms below are derived from in vitro and rodent studies only. No mechanistic pathway has been validated in a controlled human study.
All mechanistic data is derived from in vitro or rodent studies. Applicability of these pathways in humans is not established.
Animal Data
| Model | Finding | ICPS Status |
|---|---|---|
| Rat endothelial aging model | Improved endothelial cell morphology and function markers vs. untreated aged controls. Reduction in age-related endothelial deterioration scores. Khavinson VKh et al. ↗ | Preclinical |
| In vitro endothelial cell culture | Vesugen promoted endothelial cell proliferation and reduced markers of cellular senescence in aged human umbilical vein endothelial cells (HUVECs). Effect concentration-dependent. Linkova NS et al. ↗ | Preclinical |
| Aged rat vasculature | Partial restoration of eNOS expression and NO-mediated vasodilation relative to untreated aged controls. Improved endothelial cell density in aortic tissue sections. | Preclinical |
| Atherogenic lipid model | Reduced adhesion molecule upregulation and lipid accumulation in endothelial cells exposed to oxidised LDL in vitro. Proposed anti-atherogenic effect; not reproduced in independent laboratory. | Preclinical |
No finding from this section has been replicated in a controlled human trial. Animal-to-human translation for peptides is uncertain and cannot be assumed.
Human Trials
| Trial | Population | Status | ICPS Status |
|---|---|---|---|
| Observational — Elderly Vascular Biomarkers | Elderly subjects; vascular biomarker measurement during Vesugen administration. Russian-language publication; no placebo control reported. Trofimova SV et al. ↗ | — | Incomplete |
| All other indications | — | — | No Data |
Vesugen has no FDA, EMA, or Health Canada–approved indications and no published Phase III trial data for any condition as of 2026.
Safety & Side Effects
No significant toxicity reported in the limited animal studies published. As a short tripeptide, Vesugen is expected to be rapidly degraded by proteases; systemic accumulation is unlikely. However, the overall characterisation of its safety profile is thin — the absence of reported toxicity reflects the scarcity of research rather than a well-established safety record.
Proposed pro-endothelial and angiogenic mechanisms could theoretically interact with vascular pathologies, existing cardiovascular disease, or active malignancy. Long-term effects on endothelial behaviour are entirely unknown. Caution is warranted in any population with vascular disease who is under active medical treatment.
- Very limited English-language self-reporting in biohacker community
- Injection site reactions (redness, mild soreness) possible
- No serious adverse events reported in available literature
- No pharmacovigilance database exists for Vesugen
- Long-term effects in humans are completely unknown
- Active or suspected malignancy
- Existing cardiovascular disease under treatment
- Pregnancy or breastfeeding
- Immunosuppressive or anticoagulant therapy
- Children and adolescents
Vesugen is not approved by the FDA, EMA, or Health Canada for any medical indication. It is classified as a research compound and is not legal for human therapeutic use in most jurisdictions. Procurement and use outside of registered clinical trials carries regulatory and unknown health risks.
References
Research disclaimer. CompoundProfile publishes summaries of available scientific literature for educational purposes only. This page does not constitute medical advice and should not be interpreted as an endorsement of Vesugen for any therapeutic use. Consult a licensed healthcare professional before considering any research compound. All evidence gradings reflect the state of published literature as of August 2026 and are assessed independently by ICPS.
Community Commentary
Selected discussion from r/Peptides · Curated for signal, not volume
The Khavinson framework is worth taking seriously as a hypothesis — the idea that short tissue-derived peptides could act as tissue-specific gene-regulatory signals isn't biologically absurd. Short peptides can cross cell membranes and interact with nuclear proteins. The problem with Vesugen specifically is that the evidence is thinner than even Epithalon or Thymalin, and those already have a weak translational record. If you're interested in the Khavinson series, Epithalon has at least accumulated enough data to evaluate. Vesugen is a couple of cell culture papers and some elderly Soviet subjects.
Agreed. The entire Khavinson series suffers from the replication problem — there's essentially zero work from independent labs outside St. Petersburg. For compounds like Epithalon where the data is richer and some of the longevity results are striking, you can at least engage with the evidence debate. For Vesugen, there isn't really a debate yet because there isn't enough evidence to have one.
The vascular aging target is legitimate — endothelial dysfunction is probably the most upstream driver of cardiovascular disease, and there's a real gap in interventions that specifically address endothelial biology rather than just downstream lipid or clotting parameters. The frustrating thing about Vesugen is that the target is interesting and the mechanistic hypothesis is coherent, but the research program appears to have stalled completely. No human PK data, no dose-response characterisation, no independent replication. The compound's potential can't be evaluated from what's currently available.
I'd push back a little on treating the language barrier as the main limitation here. A lot of the Khavinson work has been translated or published in bilingual journals, and when you read it, the methodological quality is the actual problem — small sample sizes, no blinding described, outcomes that are soft biomarkers rather than clinical endpoints. The issue isn't access to the data, it's that the data that exists doesn't clear a basic evidentiary bar regardless of language. I'd want to see Vesugen in a properly powered RCT with a preregistered protocol before getting excited about it.
Fair point. The bar for a small pilot study that would actually tell you something useful isn't that high — you'd need reliable compounding, a validated biomarker panel (FMD, ICAM-1, eNOS expression in PBMCs as a proxy), and 30-50 subjects. The fact that none of this has been done after 20+ years of claimed research on the compound is itself informative.
What I appreciate about ICPS profiling these less-studied Khavinson compounds is that it keeps the claims honest. The longevity community sometimes treats Epithalon, Vesugen, and Thymalin as a kind of validated suite just because they've been around for decades and come from a structured research tradition. But long history in a single lab isn't the same as validated evidence. Vesugen in particular has so little published data that the appropriate epistemic posture is "interesting hypothesis, unresolved." That's a long way from the vendor language of arterial reversal and cardiovascular protection.